Kezar bags a $50M B round in wake of PhIa study; Bayer kicks back a partnered drug
→ Right on the heels of what it calls a successful Phase Ia study for its immunoproteasome inhibitor, South San Francisco-based Kezar Life Sciences has …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
